Fosfomycin Disodium Salt An antibiotic enzyme inhibitor

Fosfomycin Disodium Salt (CAS 26016-99-9)

Fosfomycin Disodium Salt | CAS 26016-99-9 is rated 5.0 out of 5 by 1.
  • y_2019, m_3, d_23, h_16
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.11
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_211542, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 82ms
  • REVIEWS, PRODUCT
Synonym: Phosphomycin Disodium Salt; Disodium (1R,2S)-(1,2-epoxypropyl)phosphonate
Application: An antibiotic enzyme inhibitor
CAS Number: 26016-99-9
Molecular Weight: 182.02
Molecular Formula: C3H5O4P•2Na
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Fosfomycin Disodium Salt is an antibiotic produced by Streptomyces fradiae. It is a phosphoenolpyruvate analog that irreversibly inhibits UDP-GlcNAc enolpyruvyl tranferase (MurA), an enzyme involved in bacterial cell wall biosynthesis. This, in turn, inhibits the production of N-acetylmuramic acid, an essential element of the peptidoglycan cell wall. Fosfomycin disodium salt concentrates in the kidney and bladder, thereby reducing nephrotoxicity and ototoxicity of platinum-containing antitumor agents.


References

Goto, M., et al.: Antimicrob. Agents Chemother., 20, 393 (1981),

Physical State :
Solid
Solubility :
Soluble in Water
Storage :
Store at 4° C
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
RTECS :
SZ7902000
PubChem CID :
73491
MDL Number :
MFCD00056853
EC Number :
247-409-2
Beilstein Registry :
4604425
SMILES :
C[C@H]1[C@H](O1)P(=O)([O-])[O-].[Na+].[Na+]

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 64ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Marqu s Marqu s, C. et al. (PubMed 26297246) characterized the effects of Fosfomycin on in vitro biofilm formed by a representative strain of meticillin-susceptible Staphylococcus aureus (MSSA) isolated from a bone infection. The presence of Fosfomycin during the initial steps of biofilm formation resulted in significant decreases in the number of sessile viable bacteria at the highest concentrations tested. -SCBT Publication Review
Date published: 2015-07-16
  • y_2019, m_3, d_23, h_16
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.11
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_211542, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 85ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.